Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AMG 747

Drug Profile

AMG 747

Alternative Names: AMG747

Latest Information Update: 01 May 2014

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen
  • Class Acetic acids; Antipsychotics; Fluorobenzenes; Piperazines; Small molecules
  • Mechanism of Action Glycine transporter 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Schizophrenia

Most Recent Events

  • 17 Feb 2014 Discontinued - Phase-II for Schizophrenia in Australia, Canada, Czech Republic, France, Malaysia, New Zealand, Poland, Russia, Singapore, Spain, United Kingdom and USA (PO) prior to February 2014
  • 14 Jun 2013 Amgen terminates two phase II trials in Schizoprenia in the USA, Australia, Canada, Czech Republic, France, Malaysia, New Zealand, Poland, Russian, Singapore, Spain and the United Kingdom (NCT01568229; NCT01568216)
  • 09 May 2013 Phase-II clinical trials in Schizophrenia in United Kingdom, Singapore, Malaysia, Russia, Poland, Spain, France, Czech Republic (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top